Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Producing Homogeneous ADCs with Combination Warheads

Presentations

Producing Homogeneous ADCs with Combination Warheads Hallam, Trevor, Producing Homogeneous ADCs with Combination Warheads Presented at the 4th World ADC Summit, San Francisco (PDF) Read...

Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter

Events

Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter Scientific American Guest Blog Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter By: Trevor J. Hallam Read...

Cell-Free Translation of Peptides and Proteins: From High Throughput Screening to Clinical Production

Presentations

Cell-Free Translation of Peptides and Proteins: From High Throughput Screening to Clinical Production Christopher J Murray, and Ramesh Baliga, Cell-free translation of peptides and proteins: from high throughput screening to clinical production,  Current Opinion in...

Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer

Press Releases

Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer SAN FRANCISCO, Jan. 31, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology,...

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

Press Releases

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates SAN FRANCISCO, Jan. 3, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s...

Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies

Press Releases

Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies SAN FRANCISCO, Dec. 18, 2012 – Sutro Biopharma today announced a collaboration with Celgene Corporation to design and...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.